Vasculitis (plural: vasculitides), often known as angiitis, is a series of disorders characterized by inflammation of blood vessels. Vasculitis is characterized by inflammation of the arteries, veins, and/or capillaries. Without regard to age, the illness can affect both males and females equally. There are several types of vasculitis, and their scientific features differ greatly in terms of severity, symptoms, and illness duration. It is determined by the type of blood vessels impacted by the condition. Vasculitis is an immune-system-related illness. Here, the immune system ceases to provide protection against infection and, as a result, attacks its own. The exact cause of vasculitis is unknown; however, variables initiating the condition include an individual's genetic composition, blood malignancies, immune system disorders (e.g., rheumatoid arthritis), infections (e.g., hepatitis B), and medication reaction. Inflammation of blood arteries can result in a number of consequences. It may obstruct the course of blood flow, causing organs to malfunction.
According to Vasculitis UK, the most common causes of vasculitis are inherited or environmental. Furthermore, there is a paucity of regulatory-approved therapy. According to the National Center for Biotechnology Information, rituximab (Biogen Idec/Genentech, Rituxan) was the first and only FDA-approved therapeutic option for vasculitis in 2011. This has prompted governments and pharmaceutical companies to work together to find new medications for the treatment of vasculitis. Furthermore, early diagnosis is one of the most important variables in illness therapy. The advancement of technology and enhanced diagnostics, as well as backing from governments and regulatory organizations throughout the world, will drive the worldwide vasculitis treatment market forward.
According to the American Heart Association, while it has not been shown that inflammation of arteries or veins causes cardiovascular disease, it is common in stroke and heart disease patients and is considered an atherogenic (fat deposition in arteries) reaction. As the frequency of cardiovascular disorders rises, more individuals will seek vasculitis diagnosis and therapy. Although it has not been shown that inflammation causes cardiovascular disease, it is widespread in heart disease and stroke patients and is regarded to be an indication of an atherogenic response, which will drive the worldwide vasculitis treatment market forward.